Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform.
Yifeng XiaXiaodong JiIn Sock JangChristine SurkaChristy HsuKai WangMark RolfeNeil BenceGang LuPublished in: Communications biology (2021)
The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generation PRISM platform combining Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene editing, cell line DNA barcoding and next-generation sequencing to enable genetic and/or pharmacological assessment of target addiction in hundreds of cell lines simultaneously. Both compound and CRISPR-knockout PRISM screens well recapitulated the results from individual assays and showed high consistency with a public database.
Keyphrases
- high throughput
- crispr cas
- genome wide
- drug discovery
- papillary thyroid
- genome editing
- healthcare
- copy number
- single cell
- circulating tumor
- squamous cell
- primary care
- dna methylation
- squamous cell carcinoma
- mental health
- emergency department
- single molecule
- quality improvement
- risk assessment
- human health
- circulating tumor cells